Division: Pharmacy Services Subject: Prior Authorization Criteria Original Development Date: Original Effective Date:

First Page		Document Content
Date: 2014-08-22 13:13:18 Bristol-Myers Squibb Angiology Vascular endothelial growth factor Paclitaxel Stomach cancer Esophageal cancer Ramucirumab Metastasis Bevacizumab Medicine Chemistry Gastrointestinal cancer		Division: Pharmacy Services Subject: Prior Authorization Criteria Original Development Date: Original Effective Date: Add to Reading List Source URL: www.fdhc.state.fl.us Download Document from Source Website File Size: 239,11 KB Share Document on Facebook

	CLINICAL TRIAL OUTCOME DATABASE (CTOD) Novartis RA: Model-Based Meta-Analysis for Quantifying Paclitaxel Dose Response in Cancer Patients Authors D Lu, A Joshi, H Li, N Zhang, MM Ren, Y Gao, R Wada and JY Jin DocID: 1uOYW - View Document
	2013 年 Ⅰ．原著論文 1) Yamada K, Tanabe H, Imai M, Jobo T, Kudo K, Fujiwara H, Nagata C, Furuya K, Suzuki M, Ochiai K, Tanaka T, Yasuda M. Feasibility study of paclitaxel plus DocID: 1uc4P - View Document
	Final Results of a Phase 1b of Tarextumab (OMP-59R5) (anti-Notch2/3 antibody) in Combination with Nab-paclitaxel and Gemcitabine (Nab P+Gem) in Patients (pts) with Untreated Metastatic Pancreatic Cancer (mPC): ALPINE Stu DocID: 1t7ew - View Document
	Phase 1b study of WNT inhibitor ipafricept (IPA, decoy receptor for WNT ligands) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC) Colin Weekes,1 DocID: 1t6TW - View Document
	Preclinical and Clinical Activity of Anti-DLL4 (Demcizumab) in Combination with Gemcitabine Plus nab-Paclitaxel in Pancreatic Cancer Manuel Hidalgo, Antonio Cubillo, Robert Stagg, Jakob Dupont, Wan-Ching Yen**, Tim DocID: 1t3Wy - View Document